Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.

Spikevax (elasomeran) - Moderna

Comirnaty (tozinameran) - Pfizer, Fosun Pharma, BioNTech

ARCT-154 - Arcturus Therap, Meiji Seika

http://www.ncbi.nlm.nih.gov/pubmed/38141632

Benjamin Greener; Iori Okura; Judd L Walson; Manabu Kanai; Takeshi Minamida; Toru Kurosawa; Yasuhiro Iwama; Ye Zhang; Yoshiaki Oda; Yuji Kumagai; Yukihiro Yagi

Dec 24, 2023